Since then, a multitude of tissue based CDx tests have been approved by the United States Food and Drug Administration (FDA) in single tumor types such as BRAF V600E in melanoma and EGFR exon 19 deletions in non-small cell lung cancer (NSCLC) [1]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.